MX2015005837A - Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo. - Google Patents
Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo.Info
- Publication number
- MX2015005837A MX2015005837A MX2015005837A MX2015005837A MX2015005837A MX 2015005837 A MX2015005837 A MX 2015005837A MX 2015005837 A MX2015005837 A MX 2015005837A MX 2015005837 A MX2015005837 A MX 2015005837A MX 2015005837 A MX2015005837 A MX 2015005837A
- Authority
- MX
- Mexico
- Prior art keywords
- ulcerative colitis
- treatment
- long term
- term stability
- solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261724678P | 2012-11-09 | 2012-11-09 | |
| PCT/US2013/069449 WO2014074995A1 (en) | 2012-11-09 | 2013-11-11 | Enema composition for treatment of ulcerative colitis having long term stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005837A true MX2015005837A (es) | 2015-09-24 |
Family
ID=50682294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005837A MX2015005837A (es) | 2012-11-09 | 2013-11-11 | Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8809308B2 (enExample) |
| EP (2) | EP2916818B1 (enExample) |
| JP (1) | JP6423353B2 (enExample) |
| AU (1) | AU2013342069B2 (enExample) |
| CA (1) | CA2891090A1 (enExample) |
| ES (1) | ES2622372T3 (enExample) |
| MX (1) | MX2015005837A (enExample) |
| WO (1) | WO2014074995A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| EP2916818B1 (en) * | 2012-11-09 | 2017-02-01 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
| CN107249595A (zh) | 2015-01-26 | 2017-10-13 | Ea制药株式会社 | 灌肠剂 |
| WO2018122086A1 (en) * | 2016-12-28 | 2018-07-05 | Dr. Falk Pharma Gmbh | Enema for rectal application |
| EP4233872B1 (en) | 2018-10-24 | 2025-07-02 | Ferring B.V. | Mucoadhesive pharmaceutical compositions of corticosteroids |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211777A (en) | 1977-11-25 | 1980-07-08 | Fisons Limited | Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid |
| WO1981002671A1 (en) | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
| US4657900A (en) | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
| EP0382066A3 (de) | 1989-02-09 | 1992-01-08 | ASTA Medica Aktiengesellschaft | Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum |
| GB8909559D0 (en) | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
| US5378470A (en) | 1989-07-25 | 1995-01-03 | Henning Berlin Gmbh | Rectally administered pharmaceutical preparation |
| PT95826B (pt) | 1989-11-09 | 1997-11-28 | Asta Medica Ag | Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico |
| DE4218572A1 (de) | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
| US5569670A (en) | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US8178516B2 (en) | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US5563131A (en) | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| DE19509806A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Lagerstabile Arzneiformen |
| US5817630A (en) | 1997-03-18 | 1998-10-06 | Austin Nutriceutical Corporation | Glutathione antioxidant eye drops |
| US6197749B1 (en) | 1997-10-29 | 2001-03-06 | Ajinomoto Co., Inc. | Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes |
| WO1999055326A1 (en) | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
| AR042572A1 (es) | 1999-04-02 | 2005-06-29 | Sod Conseils Rech Applic | Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos |
| US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| EP1172110A3 (de) | 2000-07-07 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen |
| JP2005512946A (ja) | 2001-05-09 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 選択的免疫調節法 |
| US20030235571A1 (en) | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| US7195766B2 (en) | 2002-09-10 | 2007-03-27 | National Jewish Medical And Research Center | Product and process for liquefaction of mucus or sputum |
| US7157444B2 (en) | 2002-12-21 | 2007-01-02 | Deanna Jean Nelson | Aminosalicylate derivatives for treatment of inflammatory bowel disease |
| EP1599184A4 (en) | 2003-02-04 | 2009-06-24 | Chrysalis Tech Inc | FULLY HALOGENATED FLUOROCARBON HYDROGEN AND HYDROFLUOROCHLOROUS HYDROGEN FUELS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| US20060264408A1 (en) | 2003-03-06 | 2006-11-23 | Haj-Yehia Abdullah I | Sod minic multifunctional compounds for treating inflammatory bowel disease |
| CA2530407A1 (en) | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| US8916546B2 (en) * | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| US20100112088A1 (en) | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| EP1888033B1 (en) * | 2005-06-09 | 2014-02-19 | Meda AB | Method and composition for treating inflammatory disorders |
| US8067433B2 (en) * | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| WO2008031013A1 (en) | 2006-09-08 | 2008-03-13 | Gene Logic Inc. | Method for treating inflammatory diseases of the digestive tract |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| EP2392321A1 (en) * | 2007-06-13 | 2011-12-07 | Jay Pravda | Combined composition for rectal administration for the treatment of inflammatory bowel disease |
| DK3354276T3 (da) * | 2007-11-13 | 2020-03-30 | Meritage Pharma Inc | Sammensætninger til behandlingen af gastrointestinal inflammation |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| MX2011010673A (es) | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Formulaciones de nanoparticulas y usos de las mismas. |
| EP2916818B1 (en) * | 2012-11-09 | 2017-02-01 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
-
2013
- 2013-11-11 EP EP13852751.0A patent/EP2916818B1/en not_active Not-in-force
- 2013-11-11 EP EP17153669.1A patent/EP3181120A1/en not_active Withdrawn
- 2013-11-11 WO PCT/US2013/069449 patent/WO2014074995A1/en not_active Ceased
- 2013-11-11 AU AU2013342069A patent/AU2013342069B2/en not_active Ceased
- 2013-11-11 ES ES13852751.0T patent/ES2622372T3/es active Active
- 2013-11-11 JP JP2015541981A patent/JP6423353B2/ja not_active Expired - Fee Related
- 2013-11-11 CA CA2891090A patent/CA2891090A1/en not_active Abandoned
- 2013-11-11 MX MX2015005837A patent/MX2015005837A/es unknown
- 2013-11-11 US US14/076,560 patent/US8809308B2/en not_active Expired - Fee Related
-
2014
- 2014-07-08 US US14/326,096 patent/US9238037B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2916818B1 (en) | 2017-02-01 |
| JP2015536995A (ja) | 2015-12-24 |
| US20140135299A1 (en) | 2014-05-15 |
| AU2013342069A1 (en) | 2015-05-21 |
| US8809308B2 (en) | 2014-08-19 |
| US20140323449A1 (en) | 2014-10-30 |
| EP3181120A1 (en) | 2017-06-21 |
| EP2916818A1 (en) | 2015-09-16 |
| US9238037B2 (en) | 2016-01-19 |
| JP6423353B2 (ja) | 2018-11-14 |
| WO2014074995A1 (en) | 2014-05-15 |
| CA2891090A1 (en) | 2014-05-15 |
| ES2622372T3 (es) | 2017-07-06 |
| AU2013342069B2 (en) | 2018-05-31 |
| EP2916818A4 (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081983A1 (es) | Articulo de dosis unitaria soluble que comprende un polimero cationico | |
| BR112017004798A2 (pt) | composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal | |
| CL2015003725A1 (es) | Método para suprimir la corrosión de una superficie metálica corrosible que comprende: introducir una dosis de inhibidor de corrosión en un primer tiempo; reducir la cantidad de inhibidor; y mantener una segunda concentración de inhibidor en un segundo tiempo menor del 25% de la concentración inicial | |
| MX2016015636A (es) | Formulaciones cannabinoides estables. | |
| CL2015000574A1 (es) | Formulaciones acuosas estables de adalimumab. | |
| PE20180230A1 (es) | Composicion hemostatica y dispositivo hemostatico (variantes) | |
| MX2016012730A (es) | Estructuras de cateter para reducir en uso de fluoroscopia durante procedimiento endovasculares. | |
| MX2016013793A (es) | Obturador antimicrobiano para usarse con dispositivos de acceso vascular. | |
| MX370903B (es) | Composiciones de ácido percarboxílico estables y sus usos. | |
| CL2012000412A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de quinolina de formula i, una sal o solvato farmaceuticamente aceptable del mismo, y un carbonato de metal alcalino terreo; util en el tratamiento del cancer. | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| MX2016008118A (es) | Composiciones de isoxazolina y uso de las mismas en la prevencion o tratamiento de infestaciones parasitarias en animales. | |
| CL2008001605A1 (es) | Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia. | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| MX2016000727A (es) | Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante. | |
| BR112012021638A2 (pt) | composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara. | |
| PE20150083A1 (es) | Formulacion de ibuprofeno inyectable | |
| PE20151426A1 (es) | Solucion para preservar conductos vasculares | |
| AR088016A1 (es) | Articulo absorbente | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| AR100001A1 (es) | Composiciones esporicidas clostridium difficile | |
| CL2012001835A1 (es) | Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. | |
| MX345216B (es) | Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol. |